DK2114990T5 - Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor - Google Patents

Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor

Info

Publication number
DK2114990T5
DK2114990T5 DK08726179.8T DK08726179T DK2114990T5 DK 2114990 T5 DK2114990 T5 DK 2114990T5 DK 08726179 T DK08726179 T DK 08726179T DK 2114990 T5 DK2114990 T5 DK 2114990T5
Authority
DK
Denmark
Prior art keywords
treatment
egfr
inhibitor
gene
response
Prior art date
Application number
DK08726179.8T
Other languages
English (en)
Other versions
DK2114990T3 (da
Inventor
Patrick J Muraca
Original Assignee
Nuclea Biomarkers Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclea Biomarkers Llc filed Critical Nuclea Biomarkers Llc
Application granted granted Critical
Publication of DK2114990T3 publication Critical patent/DK2114990T3/da
Publication of DK2114990T5 publication Critical patent/DK2114990T5/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08726179.8T 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor DK2114990T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90369407P 2007-02-27 2007-02-27
PCT/US2008/002602 WO2008106175A2 (en) 2007-02-27 2008-02-27 Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors

Publications (2)

Publication Number Publication Date
DK2114990T3 DK2114990T3 (da) 2012-01-16
DK2114990T5 true DK2114990T5 (da) 2012-05-07

Family

ID=39716322

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08726179.8T DK2114990T5 (da) 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
DK11008690.7T DK2413142T3 (da) 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11008690.7T DK2413142T3 (da) 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor

Country Status (6)

Country Link
US (4) US20080206777A1 (da)
EP (2) EP2114990B9 (da)
AT (1) ATE531725T1 (da)
DK (2) DK2114990T5 (da)
ES (2) ES2412432T3 (da)
WO (1) WO2008106175A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313641A1 (en) * 1997-12-12 1999-06-24 Digene Corporation Universal collection medium
US7439016B1 (en) * 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
JP2011518333A (ja) * 2008-04-17 2011-06-23 キアジェン ゲイサーズバーグ インコーポレイテッド 標的核酸の存在を判別するための合成プローブを用いた組成物、方法、およびキット
US8877436B2 (en) 2008-10-27 2014-11-04 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay on an automated platform
EP2419522A4 (en) * 2009-04-17 2012-10-31 Glen Weiss METHODS AND KITS FOR PREDICTING THE THERAPEUTIC RESULT OF TYROSINE KINASE INHIBITORS
CA2760542A1 (en) 2009-05-01 2010-11-04 Qiagen Gaithersburg, Inc. A non-target amplification method for detection of rna splice-forms in a sample
JP5826752B2 (ja) 2009-09-14 2015-12-02 キアジェン ゲイサーズバーグ インコーポレイテッド 細胞学用培地に固定された組織サンプルから核酸またはタンパク質を回収するための組成物および方法
EP2529031B1 (en) 2010-01-29 2014-07-09 QIAGEN Gaithersburg, Inc. Method of determining and confirming the presence of hpv in a sample
EP2528932B1 (en) * 2010-01-29 2016-11-30 QIAGEN Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
CA2799200A1 (en) 2010-05-19 2011-11-24 Qiagen Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
WO2012094059A2 (en) * 2010-11-10 2012-07-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing early stage non-small cell lung cancer
JP2014511182A (ja) 2011-02-24 2014-05-15 キアゲン ガイサーズバーグ アイエヌシー． Ｈｐｖ核酸を検出するための材料及び方法
CN103926408A (zh) * 2014-04-30 2014-07-16 天津医科大学肿瘤医院 一种用于预测nsclc病人预后的试剂盒及骨桥蛋白作为特异标记物的应用
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
CN116098856B (zh) * 2023-01-16 2024-06-21 四川大学华西医院 光固化水凝胶复合核酸传递系统及治疗脊髓损伤的药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US6482795B1 (en) * 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
AU7937398A (en) * 1997-07-03 1999-01-25 Asahi Kasei Kogyo Kabushiki Kaisha Novel mapk kinase
CA2318789C (en) 1998-02-25 2011-05-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cellular arrays for rapid molecular profiling
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6582946B1 (en) * 2001-03-12 2003-06-24 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US6727072B2 (en) * 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US20030194734A1 (en) 2002-03-29 2003-10-16 Tim Jatkoe Selection of markers
KR20050037510A (ko) * 2002-06-05 2005-04-22 세다르스-신나이 메디칼 센터 키나제 억제제를 사용하는 암 치료 방법
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
US20110189691A1 (en) 2011-08-04
ES2412432T3 (es) 2013-07-11
US8088589B2 (en) 2012-01-03
EP2413142A1 (en) 2012-02-01
WO2008106175A2 (en) 2008-09-04
DK2413142T3 (da) 2013-07-22
ES2376978T3 (es) 2012-03-21
WO2008106175A3 (en) 2008-11-20
US8900820B2 (en) 2014-12-02
US20120094311A1 (en) 2012-04-19
US20080206777A1 (en) 2008-08-28
ATE531725T1 (de) 2011-11-15
EP2114990B1 (en) 2011-11-02
DK2114990T3 (da) 2012-01-16
US8129125B2 (en) 2012-03-06
EP2413142B1 (en) 2013-06-05
US20090263819A1 (en) 2009-10-22
EP2114990A2 (en) 2009-11-11
EP2114990A4 (en) 2010-04-07
EP2114990B9 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
DK2114990T5 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
DE602005009702D1 (de) Esr1 und gebärmutterhalskrebs
WO2009015233A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
BR112013009376A2 (pt) métodos para determinar isótipos de anticorpos antifármacos
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BR112017006088A2 (pt) uso de painéis de genes fgfr mutantes na identificação de pacientes com câncer que serão responsivos ao tratamento com um inibidor de fgfr
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
EA201190042A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
BR112014011127A2 (pt) métodos para tratar, diagnosticar e monitorar doença de alzheimer
DK2903616T3 (da) Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer
NZ584642A (en) Factor involved in latent infection with herpesvirus, and use thereof
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
DK2019872T3 (da) Fremgangsmåde til forudsigelse af modtageligheden over for TNF-blokkere
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
EA201291228A1 (ru) Биомаркер для детекции высокогорной адаптации и высокогорного отека легких
CY1119869T1 (el) Αντικαρκινικος παραγοντας και μεθοδος προβλεψης θεραπευτικου αποτελεσματος για ασθενεις με κολοορθικο καρκινο μεταλλαξης kras
WO2010030857A3 (en) Egfr inhibitor therapy responsiveness
BR112014027413A2 (pt) biomarcadores para terapia com inibidor de iap
WO2010115997A3 (en) Method for determining survival prognosis of patients suffering from non-small cell lung cancer (nsclc)